Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.

Molecular cancer therapeutics - 1 Sept 2018

Njatcha Christian, Farooqui Mariya, Kornberg Adam, Johnson Daniel E, Grandis Jennifer R, Siegfried Jill M

Abstract excerpt

Constitutively activated STAT3 plays a critical role in non-small cell lung carcinoma (NSCLC) progression by mediating proliferation and survival. STAT3 activation in normal cells is transient, making it an attractive target for NSCLC therapy. The therapeutic potential of blocking STAT3 in NSCLC was assessed utilizing a decoy approach by ligating a double-stranded 15-mer oligonucleotide that corresponds to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to Mice, Nude

Share to Oligonucleotides, Antisense

Share to STAT3 Transcription Factor

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29891486
DOI: 10.1158/1535-7163.MCT-17-1194
PMCID: PMC6125196

Genes

STAT3
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.PMID 29891486Read ↗

First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer TherapySemantic proximity Read ↗

Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor.Semantic proximity Read ↗

Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.Semantic proximity Read ↗

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription FactorSemantic proximity Read ↗

STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genesSemantic proximity Read ↗

Targeting STAT3 in Cancer with Nucleotide TherapeuticsSemantic proximity Read ↗

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancerSemantic proximity Read ↗

Targeting Stat3 in cancer therapySemantic proximity Read ↗

A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell lineSemantic proximity Read ↗

A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κBSemantic proximity Read ↗

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.